The Center for Prostate Disease Research (CPDR) has projected that there will be over 200,000 new cancer cases and 27,000 deaths from prostate cancer in the year 2007. Prostate cancer alone accounts for roughly 29% of cancer incidences in men. According to the National Cancer Institute (NCI), a man's chance of developing prostate cancer increases drastically from 1 in 10,000 before age 39 to 1 in 45 between 40-59 and 1 in 7 after age 60. The overall probability of developing prostate cancer from birth to death being close to 1 in 6.
Traditionally either elevated Prostate Specific Antigen (PSA) level or Digital Rectal Examination (DRE) has been widely used as a standard for prostate cancer detection. For a physician to diagnose prostate cancer, a biopsy of the prostateMacCHESS, a synchrotron radiation Research Resource for macromolecular crystallography, has the overall goal of advancing the frontiers of structural biology through innovative technical research and development and user support. MacCHESS leverages the National Science Foundation investments in the Cornell High Energy Synchrotron Source (CHESS), which maintains the synchrotron radiation laboratory, and the Laboratory for Elementary Particle Physics (LEPP), which operates the storage ring. MacCHESS technical developments are driven by both core and collaborative research projects involving a broad range of macromolecules. In addition to performing technical R&D and core research, MacCHESS provides specialized instrumentation for macromolecular crystallography and a staff for user training and support. MacCHESS has established itself as one of the most productive facilities in the world for macromolecular crystallography with almost 400 papers published during